雷帕鸣用于预防肾移植后的排斥反应时应该怎样服药

As we all know, uremia is a very serious disease that can endanger people's lives. If patients are not treated in time, it will cause many adverse consequences. Kidney transplantation is a surgical method to treat uremia, but after kidney transplantation, patients will experience rejection, which will eventually affect people's health. These are medicines used to prevent rejection reactions.

Rapamin inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, rapamycin binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian sirolimus BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from the G1 phase to the S phase in the cell cycle.

So how to use rapamycin (sirolimus) if rejection occurs after kidney transplantation?

To clinically explore the clinical efficacy and safety of rapamycin (sirolimus) in renal transplantation. Start taking rapamycin within 48 hours after organ transplantation, with a loading dose of 6 mg and a maintenance dose of 2 mg. In the experiment, a total of 23 patients with cadaveric kidney transplantation were given triple immunosuppressive therapy with rapamycin combined with cyclosporine and glucocorticoids.

Results: 22 patients completed 6-12 months of follow-up. The incidence rates of acute rejection (AR) at 6 and 12 months were 13.6% (3 cases/22 cases) and 15.8% (3 cases/19 cases) respectively. AR patients were reversed after methylprednisolone pulse treatment and continued to be followed up for more than half a year. No recurrence of AR was found. The adverse reaction of taking rapamycin (sirolimus) was hyperlipidemia (56.5%, 13 cases/23 cases). After reducing the dosage or applying lipid-lowering drugs, the patient's blood lipids dropped to normal or slightly higher than normal levels. Graft vascular disease and cardiovascular complications have not increased so far during follow-up.

The above are the issues related to rapamycin (sirolimus) for the treatment of post-kidney transplant medication provided by the editor of Medical Companion Travel. In summary, (sirolimus) has an ideal effect in the treatment of kidney transplantation and is the first choice for kidney transplant patients.

Recommended related hot articles: /newsDetail/80209.html